Autres langues Fuso Pharmaceutical Industries,Ltd.

Actions

4538

JP3823600006

Produits pharmaceutiques

Temps Différé Japan Exchange 02:19:06 08/10/2026			Varia. 5j.	Varia. 1 janv.
2 113,00 ^JPY	-1,40%		-4,52%	-8,73%

30/09	Fuso Pharmaceutical Industries, Ltd. conclut un contrat de conception-réalisation avec Chiyoda X-ONE Engineering Corporation pour sa deuxième usine d’Okayama	CI
10/08	Fuso Pharmaceutical Industries, Ltd. publie ses résultats pour le premier trimestre clos le 30 juin 2026	CI

Autres langues

30/09	Fuso Pharmaceutical Industries, Ltd. Concludes Design-Build Contract with Chiyoda X-One Engineering Corporation for Okayama Second Factory
21/09	Fuso Pharmaceutical Industries,Ltd.(TSE:4538) added to S&P Global BMI Index
10/08	Fuso Pharmaceutical Industries,Ltd. Reports Earnings Results for the First Quarter Ended June 30, 2026
18/05	Fuso Pharmaceutical Industries,Ltd. Reports Earnings Results for the Full Year Ended March 31, 2026
12/05	Fuso Pharmaceutical Industries,Ltd. Provides Non-Consolidated Earnings Guidance for the Six Months Ending September 30, 2026, and Full Fiscal Year Ending March 31, 2027
12/05	Fuso Pharmaceutical Industries,Ltd. Provides Dividend Guidance for the Second Quarter-End Fiscal Year Ending March 31, 2027 and Full Year Ending March 31, 2027
12/05	Fuso Pharmaceutical Industries,Ltd. Proposes Year-End Dividend for the Fiscal Year Ended March 31, 2026, Payable on June 25, 2026
12/05	Fuso Pharmaceutical Industries,Ltd. Announces Board Changes, Effective June 24, 2026
31/03	Fuso Pharmaceutical Industries, Ltd. Concludes Syndicated Loan Agreement
17/02	Fuso Pharmaceutical Industries' Nine-Month Profit Falls 30%; Sales Rise 3%
12/02	Fuso Pharmaceutical Industries,Ltd. Reports Earnings Results for the Nine Months Ended December 31, 2025
10/11	Fuso Pharmaceutical Industries,Ltd. Announces Second Quarter-End Dividend for the Six Months Ended September 30, 2025, Payable on December 2, 2025
05/09/25	Japanese Court Shatters Previous Record For Damages Award In A Patent Infringement Case
01/08/25	Fuso Pharmaceutical Industries, Ltd. Announces Executive Officer Personnel Appointments, Effective September 1, 2025
25/06/25	Fuso Pharmaceutical Industries, Ltd. Announces Executive Changes
09/06/25	Fuso Pharma Appeals 7.47 Billion Yen Patent Ruling to Japan's Supreme Court
04/06/25	Fuso Pharmaceutical Industries Maintains Fiscal 2025 Forecasts Despite Lawsuit
28/05/25	Fuso Pharmaceutical Ordered to Pay 7.47 Billion Yen in Patent Case Over Nalfurafine Tablets
09/05/25	Fuso Pharmaceutical Industries,Ltd. Announces Dividend for Fiscal Year Ended March 31, 2025, Payable on June 26, 2025; Provides Dividend Guidance for the Second Quarter and Fiscal Year Ending March 31, 2026
09/05/25	Fuso Pharmaceutical Industries,Ltd. Provides Non-Consolidated Earnings Guidance for the First Half and Full Fiscal Year Ending March 31, 2026
31/05/24	Fuso Pharmaceutical Industries : Notice of the 101th Annual General Meeting of Shareholders
06/09/23	Tranche Update on Fuso Pharmaceutical Industries,Ltd.'s Equity Buyback Plan announced on September 5, 2023.
06/09/23	Fuso Pharmaceutical Industries,Ltd.'s Equity Buyback announced on September 5, 2023, has closed with
05/09/23	Fuso Pharmaceutical Industries,Ltd. announces an Equity Buyback for 340,000 shares, representing 3.88% for ¥735 million.
05/09/23	Fuso Pharmaceutical Industries,Ltd. authorizes a Buyback Plan.